Molecular Partners to Hold Three Poster Presentations at AACR 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),…
3,513€
-1,61%
Echtzeit-Aktienkurs Molecular Partners AG
Bid:
Ask:
Nachrichten zur Molecular Partners AG Aktie
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
…
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to…
Molecular Partners reports Q1 results
…
Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade)
…
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to…
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53…
Molecular Partners und Orano stärken Partnerschaft
Das Biotechunternehmen Molecular Partners wird künftig noch enger mit dem bisherigen Partner Orano Med zusammenarbeiten.…
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025…
Molecular Partners: A Speculative Bet On Innovative DARPin Technology
…
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),…
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to…
Molecular Partners stellt bei ASCO-Kongress positive Studiendaten zu MP0317 vor
Molecular Partners hat auf der Jahrestagung 2024 der American Society of Clinical Oncology (ASCO) in Chicago die endgültigen Daten einer…
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
…
Molecular Partners: Sammelklage gegen Unternehmen und Management abgewiesen
Molecular Partners hat auf dem juristischen Parkett einen Erfolg erzielt.…
Molecular Partners Announces Dismissal of Class Action Lawsuit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a…